Longitudinal Study of Painful Diabetic Neuropathy in the Zucker Diabetic Fatty Rat Model of Type 2 Diabetes: Impaired Basal G-Protein Activity Appears to Underpin Marked Morphine Hyposensitivity at 6 Months

Pain Medicine

Volumn 12, Issue 3, 2011, Pages 437-450

  Otto, Kathleen J ^a   Wyse, Bruce D ^a   Cabot, Peter J ^a   Smith, Maree T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Impaired Basal G Protein Activity; Mechanical Allodynia; Morphine Hyposensitivity; Opioid Receptor; Painful Diabetic Neuropathy; Zucker Diabetic Fatty Rats

Indexed keywords

GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; OXYCODONE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE DURATION; DRUG POTENCY; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DETERMINATION; RAT; SPINAL CORD; TREATMENT DURATION; ZUCKER DIABETIC FATTY RAT;

EID: 79953052843     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01067.x     Document Type: Article

References (57)

1. Kamijo M, Merry A, Akdas G, Cherian P, Sima A. Nerve fiber regeneration following axotomy in the diabetic BB/W-rat: The effect of ARI treatment. J Diabetes Complications 1996;10:183-91.
2. Kamiya H, Murakawa Y, Zhang W, Sima A. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005;21:448-58.
3. Pierson C, Zhang W, Murakawa Y, Sima A. Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 2003;62:260-71.
4. Sima A, Bouchier M, Christensen H. Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat, a possible early correlate of human diabetic neuropathy. Ann Neurol 1983;13:264-72.
5. Sima A, Lattimer S, Yagihashi S, Greene D. Axoglial dysjunction: A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic BB-rat. J Clin Invest 1986;77:474-84.
6. Sima A, Ristic H, Merry A, etal. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996;97:1900-7.
7. Sima A, Zhang W, Xu G, etal. A comparison of diabetic polyneuropathy in type-2 diabetic BBZDR/Wor-rat and in type 1 diabetic BB/Wor-rat. Diabetologia 2000;43:786-93.
8. Schmidt R, Dorsey D, Beaudet L, Peterson R. Analysis of the Zucker diabetic fatty (ZDF) type 2 diabetic rat model suggests a neuropathic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol 2003;163:21-8.
9. Schmidt R, Dorsey D, Beaudet L, etal. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol 2004;63:450-60.
10. Sima A, Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci 2006;1084:235-49.
11. Peterson R, Shaw W, Neel M, Little L, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. ILAR J 1990;32:16-9.
12. Sugimoto K, Rashid I, Kojima K, etal. Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab Res Rev 2008;24:642-50.
13. Li F, Abatan O, Kim H, etal. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol Dis 2006;22:669-76.
14. Zhuang H, Wuarin L, Fei Z, Ishii D. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther 1997;283:366-74.
15. Brussee V, Guo G, Dong Y, etal. Distal degenerative sensory neuropathy in a long term type 2 diabetes rat model. Diabetes 2008;57:1664-73.
16. Piercy V, Banner S, Bhattacharyya A, etal. Thermal, but not mechanical, nociceptive behaviour is altered in the Zucker diabetic fatty rat and is independent of glycaemic status. J Diabetes Comp 1999;13:163-9.
17. Gilhotra N, Sharma A, Singh M. Involvement of p38 MAPkinase in attenuation of antinociceptive effect of morphine in diabetic mice. Indian J Exp Biol 2007;45:654-6.
18. Nozaki C, Saitoh A, Kamei J. Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol 2006;535:145-51.
19. Nozaki C, Kamei J. Involvement of μ1-opioid receptor on oxycodone-induced antinociception in diabetic mice. Eur J Pharmacol 2007;560:160-2.
20. Singal A, Anjaneyulu M, Chopra K. Modulatory role of green tea extract on antinociceptive effect of morphine in diabetic mice. J Med Food 2005;8:386-91.
21. Torres-López J, Juárez-Rojop I, Granados-Soto V, etal. Peripheral participation of cholecystokinin in the morphine-induced peripheral antinociceptive effect in non-diabetic and diabetic rats. Neuropharmacology 2007;52:788-95.
22. Nielsen C, Ross F, Lotfipour S, etal. Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132:289-300.
23. Chen S, Pan H. Antinociceptive effect of morphine, but not μ opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003;99:1409-14.
24. Courteix C, Bourget P, Caussade F, etal. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J Pharmacol Exp Ther 1998;285:63-70.
25. Chen S, Sweigart K, Lakoski J, Pan H. Functional μ opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 2002;97:1602-8.
26. Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T. Quantitative assessment of allodynia in the rat paw. J Neurosci Methods 1994;53:55-63.
27. Calcutt N, Chaplan S. Spinal pharmacology of tactile allodynia in diabetic rats. Br J Pharmacol 1997;122:1478-82.
28. -{up triangle, open}{up triangle, open}CT method. Methods 2001;25:402-8.
29. Kamei J, Ohashi Y, Aoki R, Kawasima N, Kasuya Y. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists. Brain Res 1992;571:199-203.
30. 2-opioid receptors. Life Sci 1994;55:121-6.
31. Zurek J, Nadeson R, Goodchild C. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain 2001;90:57-63.
32. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998a;352:837-53.
34. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998b;352:854-65.
35. Arnér S, Meyerson B. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
36. Attal N. Chronic neuropathic pain: Mechanisms and treatment. Clin J Pain 2000;16:S118-30.
37. Atweh S, Kuhar M. Autoradiographic localization of opiate receptors in rat brain. Brain Res 1977;129:1-12.
38. Dickenson A, Sullivan A, Roques B. Evidence that endogenous enkephalins and a δ opioid receptor agonist have a common site of action in spinal antinociception. Eur J Pharmacol 1988;148:437-9.
39. Heyman J, Mulvaney S, Mosberg H, Porreca F. Opioid δ-receptor involvement in supraspinal and spinal antinociception in mice. Brain Res 1987;420:100-8.
40. Millan M, Członkowski A, Herz A. Evidence that μ-opioid receptors mediate midbrain "stimulation-produced analgesia" in the freely moving rat. Neuroscience 1987;22:885-96.
41. Millan M, Członkowski A, Lipkowski A, Herz A. κ-Opioid receptor-mediated antinociception in the rat. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther 1989;251:342-50.
42. Wamsley J, Zarbin M, Young W, Kuhar M. Distribution of opiate receptors in the monkey brain: An autoradiographic study. Neurosci 1982;7:595-613.
43. Hall K, Liu J, Sima A, Wiley J. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 2001;86:760-70.
44. oα. J Neurochem 2003;86:1006-14.
45. Banday A, Frazili F, Marwaha A, Lokhandwala M. Mitogen-activated protein kinase upregulation reduces renal D1 receptor affinity and G-protein coupling in obese rats. Kidney Int 2007;71:397-406.
46. Chavez M, Seeley R, Havel P, etal. Effect of a high-fat diet on food intake and hypothalamic neuropeptide gene expression in streptozotocin diabetes. J Clin Invest 1998;102:340-6.
47. Han H, Park S. Alteration of the gene and protein levels of insulin-like growth factors in streptozotocin-induced diabetic male rats. J Vet Med Sci 2006;68:413-9.
48. Ishii S, Kamegai J, Tamura H, etal. Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology 2002;143:4934-7.
49. Ndisang J, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes. Am J Physiol Endocrinol Metab 2009;296:E829-41.
50. Vishwakarma S, Sonawane R, Rajani M, Goyal R. Evaluation of effect of aqueous extract of Enicostemma littorale Blume in streptozotocin-induced type 1 diabetic rats. Indian J Exp Biol 2010;48:26-30.
51. Wenzel P, Daiber A, Oelze M, etal. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008;198:65-76.
52. Yu J, Zhang Y, Sun S, etal. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol 2006;84:579-87.
53. Finegood D, McArthur M, Kojwang D, etal. β-cell mass dynamics in Zucker diabetic fatty rats. Diabetes 2001;50:1021-9.
54. Gyte A, Pritchard L, Jones H, Brennand J, White A. Reduced expression of the KATP channel subunit, Kir6.2, is associated with decreased expression of neuropeptide Y and agouti-related protein in the hypothalami of Zucker diabetic fatty rats. J Neuroendocrinol 2007;19:941-51.
55. Király M, Bates H, Kaniuk N, etal. Swim training prevents hyperglycemia in ZDF rats: Mechanisms involved in the partial maintenance of β-cell function. Am J Physiol Endocrinol Metab 2008;294:E271-83.
56. Shibata T, Takeuchi S, Yokota S, etal. Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000;130:495-504.
57. Forcheron F, Basset A, Abdallah P, etal. Diabetic cardiomyopathy: Effects of fenofibrate and metformin in an experimental model-the Zucker diabetic rat. Cardiovasc Diabetol 2009;24:8-16.